Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Gerwin Huls*, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Sohne, Rien van Marwijk Kooy, Dries DeerenMarjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Lowenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4267-4277
Number of pages11
JournalBlood advances
Volume4
Issue number18
DOIs
Publication statusPublished - 22 Sep 2020

Keywords

  • ACUTE MYELOID-LEUKEMIA
  • MINIMAL RESIDUAL DISEASE
  • HYPOMETHYLATING AGENT THERAPY
  • CONVENTIONAL CARE REGIMENS
  • MYELODYSPLASTIC SYNDROME
  • AZACITIDINE THERAPY
  • TREATMENT RESPONSE
  • CLINICAL-RESPONSE
  • SURVIVAL
  • TRIAL

Cite this